Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Aardvark Adventures -- Ignore unavailable to you. Want to Upgrade?

To: ~digs who wrote (5171)	7/15/2008 11:47:00 PM
From: ~digs	Read Replies (1) \| Respond to of 7944

With a dividend yield hovering around 7% and a recent deal with Indian generic drug maker Ranbaxy to delay a copycat version of the world’s best selling drug Lipitor (with $12.7 billion in 2007 sales) for over one year until late 2011, shares of Pfizer (PFE) merit a buy below $18 per share for both income investors and those seeking a safe haven investment during the current bear market. straightstocks.com